Back

Beta blockers and renin-angiotensin-aldosterone system inhibitors after type 2 myocardial infarction, a target trial emulation study

30 August 2026 (12:15 - 12:45)
Organised by: Logo
Congress Presentation Part of: Innovations in post-infarction care: cardiometabolic, molecular, and haemodynamic approaches Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Anton Gard

Uppsala University Hospital, Uppsala (Sweden)

3 More presentations in this session

Presentation thumbnail
Hemodynamic impact of low-dose dobutamine in patients with acute myocardial infarction at risk of cardiogenic shock – a randomized clinical trial
Doctor S. Holle (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Comparison of oxidative and tissue stress biomarkers and platelet activation in myocardial infarction treated with prasugrel or ticagrelor
Doctor T. Vichova (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitor enhances mitochondrial stress resistance without altering ATP production in patients with ST-elevation myocardial infarction
Miss N. Apaijai (Chiang Mai, TH)
Abstract Slides Video

Access the full session

Session thumbnail
Innovations in post-infarction care: cardiometabolic, molecular, and haemodynamic approaches

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
ACEi/ARB treatment in patients with myocardial infarction and preserved left ventricular ejection fraction does not confer a benefit: a target trial emulation
31 August 2025
thumbnail
Congress Presentation
Cardiac rehabilitation and secondary prevention goals one year after myocardial infarction
28 August 2026
thumbnail
Congress Presentation
Beta-blockers in patients with uncomplicated arterial hypertension: data from the Campania Salute Network Registry
29 August 2026
thumbnail
Congress Presentation
Comparative effectiveness of probucol versus ezetimibe in statin-treated patients with established atherosclerotic cardiovascular disease
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources